Erasca is a developer of oncology drugs intended to provide precision oncology options.
Erasca has raised $632.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Erasca's investors include Andreessen Horowitz, ARCH Venture Partners, Cormorant Asset Management, OrbiMed, Invus.
Erasca is headquartered in San Diego, United States.
Erasca is a developer of oncology drugs intended to provide precision oncology options.
Erasca is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Erasca — Funding & Investors." VCBacked, July 13, 2026, https://www.vcbacked.co/company/erasca. Accessed August 13, 2026.
VCBacked. (2026). Erasca — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/erasca
{{cite web |title=Erasca — Funding & Investors |url=https://www.vcbacked.co/company/erasca |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated